Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma.
Authors
Lee, Rebecca JGremel, Gabriela
Marshall, A
Myers, K
Fisher, N
Dunn, J
Dhomen, Nathalie
Corrie, P
Middleton, M
Lorigan, Paul C
Marais, Richard
Affiliation
Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, UKIssue Date
2017-11-03
Metadata
Show full item recordAbstract
Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients with resected melanoma.Citation
Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. 2017 Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx717PubMed ID
29112704Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx717
Scopus Count
Collections
Related articles
- Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
- Authors: Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, Gyorki DE, Oudit D, Dawson MA, Hicks RJ, Lorigan P, McArthur GA, Marais R, Wong SQ, Dawson SJ
- Issue date: 2019 May 1
- Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
- Authors: Lee JH, Saw RP, Thompson JF, Lo S, Spillane AJ, Shannon KF, Stretch JR, Howle J, Menzies AM, Carlino MS, Kefford RF, Long GV, Scolyer RA, Rizos H
- Issue date: 2019 May 1
- Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.
- Authors: Lee JH, Menzies AM, Carlino MS, McEvoy AC, Sandhu S, Weppler AM, Diefenbach RJ, Dawson SJ, Kefford RF, Millward MJ, Al-Ogaili Z, Tra T, Gray ES, Wong SQ, Scolyer RA, Long GV, Rizos H
- Issue date: 2020 Aug 1
- Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
- Authors: Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford RF, Rizos H, Carlino MS
- Issue date: 2018 May 1
- Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
- Authors: Seremet T, Planken S, Schreuer M, Jansen Y, Delaunoy M, El Housni H, Lienard D, Del Marmol V, Heimann P, Neyns B
- Issue date: 2018 Feb